CEACAM5-TOPO1 ADC (Bristol-Myers Squibb Company)

N/A

Report date: 2025/12/29 15:46:41

Base Information

Drug NameCEACAM5-TOPO1 ADC (Bristol-Myers Squibb Company)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CEACAM5
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A